THERAPY DOSSIER · th-5fe2adde5f21

Nifuroxazide

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL244888 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Nifuroxazide; Ercefuryl 200
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05754996 ↗PHASE3completed

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

Hepatic Encephalopathy

Enrolment: 80 · Results not recorded

NCT05988528 ↗PHASE2/PHASE3completed

Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patients With Ulcerative Colitis

Inflammatory Bowel Diseases

Enrolment: 50 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32504751 ↗2020Reported benefit

A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.

RatEndotoxin/LPSSprague-DawleyMaleAdministered in either a prophylactic or a curative regimen relative to lipopol…

Model: Lipopolysaccharide-induced acute lung injury and myocarditis

Nifuroxazide improved lung and heart histology and reduced inflammatory infiltration, lowered serum injury biomarkers, improved oxidative status and inhibited TLR4/NLRP3/IL-1beta signalling in both prophylactic and curative regimens.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…